NO2015002I1 - Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav - Google Patents

Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav

Info

Publication number: NO2015002I1
Authority: NO; Norway
Prior art keywords: ataluren; oxadiazol; solvates; fluorophenyl; pharmaceutically acceptable
Prior art date: 2003-04-11

Application number

NO2015002C

Other languages

English (en)

Other versions

NO2015002I2 (no

Original Assignee

Ptc Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2015-02-03

Publication date

2015-02-16

2015-02-03 Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc

2015-02-03 Publication of NO2015002I2 publication Critical patent/NO2015002I2/no

2015-02-16 Publication of NO2015002I1 publication Critical patent/NO2015002I1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Ophthalmology & Optometry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO2015002C 2003-04-11 2015-02-03 Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav NO2015002I1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46198803P	2003-04-11	2003-04-11
PCT/US2004/011106 WO2004091502A2 (en)	2003-04-11	2004-04-09	1,2,4-oxadiazole benzoic acid compounds

Publications (2)

Publication Number	Publication Date
NO2015002I2 NO2015002I2 (no)	2015-02-03
NO2015002I1 true NO2015002I1 (no)	2015-02-16

Family

ID=33299886

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20055314A NO332843B1 (no)	2003-04-11	2005-11-10	1,2,4-oksadiazolbenzosyreforbindelser, anvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse.
NO2015002C NO2015002I1 (no)	2003-04-11	2015-02-03	Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20055314A NO332843B1 (no)	2003-04-11	2005-11-10	1,2,4-oksadiazolbenzosyreforbindelser, anvendelse derav og farmasoytisk sammensetning inneholdende en slik forbindelse.

Country Status (30)

Country	Link
US (17)	US6992096B2 (no)
EP (9)	EP2910551B1 (no)
JP (2)	JP4851933B2 (no)
KR (1)	KR101134188B1 (no)
CN (2)	CN104056278B (no)
AU (1)	AU2004229487B9 (no)
BE (1)	BE2015C025I2 (no)
BR (1)	BRPI0409319B8 (no)
CA (1)	CA2521992C (no)
CR (1)	CR8086A (no)
CY (7)	CY1115870T1 (no)
DK (7)	DK3549936T3 (no)
EA (1)	EA009120B1 (no)
ES (7)	ES2624610T3 (no)
FR (1)	FR15C0030I2 (no)
HK (4)	HK1093979A1 (no)
HU (7)	HUE047569T2 (no)
IL (2)	IL171343A (no)
LU (1)	LU92698I2 (no)
MA (1)	MA27802A1 (no)
MX (1)	MXPA05010747A (no)
NO (2)	NO332843B1 (no)
NZ (1)	NZ543263A (no)
PL (7)	PL3889142T3 (no)
PT (7)	PT3549936T (no)
SI (7)	SI3345895T1 (no)
TR (1)	TR201706226T4 (no)
UA (1)	UA84420C2 (no)
WO (1)	WO2004091502A2 (no)
ZA (1)	ZA200508298B (no)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458538B1 (en) *	1999-12-14	2002-10-01	Ptc Therapeutics, Inc.	Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2004001010A2 (en) *	2002-06-21	2003-12-31	Ptc Therapeutics, Inc.	METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
AU2003252136A1 (en)	2002-07-24	2004-02-09	Ptc Therapeutics, Inc.	METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
CN104056278B (zh)	2003-04-11	2017-01-18	Ptc 治疗公司	1,2,4‑噁二唑苯甲酸化合物
US8580842B2 (en)	2003-09-30	2013-11-12	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MX2007004484A (es)	2004-10-13	2007-06-25	Ptc Therapeutics Inc	Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
EP1874306B1 (en) *	2005-04-08	2012-07-04	PTC Therapeutics, Inc.	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2012238226B2 (en) *	2005-04-08	2015-05-14	Ptc Therapeutics, Inc.	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN100378084C (zh) *	2005-08-01	2008-04-02	安徽大学	2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
CA2640013A1 (en) *	2006-02-09	2007-08-16	Enzon Pharmaceuticals, Inc.	Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US9289398B2 (en) *	2006-03-30	2016-03-22	Ptc Therapeutics, Inc.	Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
US20090221639A1 (en) *	2006-04-06	2009-09-03	Lisa Sarah Bertram	Heterocyclic GPCR Agonists
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
EP2007756B1 (en)	2006-04-07	2015-08-26	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US20070287699A1 (en) *	2006-05-01	2007-12-13	Virobay, Inc.	Antiviral agents
RU2495030C2 (ru) *	2006-09-08	2013-10-10	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Способы получения 1,2,4-оксадиазолбензойных кислот
HUE028503T2 (en) *	2006-09-25	2016-12-28	Ptc Therapeutics Inc	Crystalline Forms of 3- [5- (2-Fluorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid
WO2008130370A1 (en)	2006-09-25	2008-10-30	Ptc Therapeutics, Inc.	Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
AU2013219243B2 (en) *	2006-10-12	2016-09-08	Ptc Therapeutics, Inc.	Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2016262645B2 (en) *	2006-10-12	2018-05-17	Ptc Therapeutics, Inc.	Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
KR20160128468A (ko) *	2006-10-12	2016-11-07	피티씨 테라퓨틱스, 인크.	넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8486979B2 (en) *	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) *	2006-12-12	2008-07-10	Abbott Laboratories	Pharmaceutical compositions and their methods of use
US20110207704A1 (en) *	2006-12-15	2011-08-25	Abbott Laboratories	Novel Oxadiazole Compounds
JP2010513283A (ja) *	2006-12-15	2010-04-30	アボット・ラボラトリーズ	新規なオキサジアゾール化合物
UY30846A1 (es)	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US8283351B2 (en) *	2007-04-02	2012-10-09	Institute For Oneworld Health	Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
JP5416103B2 (ja) *	2007-06-22	2014-02-12	エフ．ホフマン−ラロシュアーゲー	イソオキサゾール−イミダゾール誘導体
WO2009013477A1 (en) *	2007-07-23	2009-01-29	Summit Corporation Plc	Compounds for treating duchenne muscular dystrophy
GB0715087D0 (en)	2007-08-03	2007-09-12	Summit Corp Plc	Drug combinations for the treatment of duchenne muscular dystrophy
TW200911237A (en)	2007-08-03	2009-03-16	Summit Corp Plc	Drug combinations for the treatment of duchenne muscular dystrophy
CA2699980C (en)	2007-08-13	2015-06-02	Divergence, Inc.	Methods for the control of plant parasitic nematodes comprising application of oxadiazole compounds to plants, seeds or soil
AU2008306885B2 (en) *	2007-10-04	2013-12-05	Merck Serono S.A.	Oxadiazole derivatives
US8404676B2 (en)	2007-10-04	2013-03-26	Merck Serono Sa	Oxadiazole diaryl compounds
CA2702094C (en)	2007-10-10	2018-05-01	Parion Sciences, Inc.	Delivering osmolytes by nasal cannula
DK2217572T3 (da)	2007-11-16	2014-02-03	Vertex Pharma	Isoquinoliner som modulatorer af ATP-bindingskassettetransportører
US8703774B2 (en)	2007-12-07	2014-04-22	AbbVie Deutschland GmbH & Co. KG	Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
MX2010006202A (es) *	2007-12-07	2011-03-04	Abbott Gmbh & Co Kg	Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CA2707669C (en) *	2007-12-07	2016-07-05	Wilfried Braje	5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
ES2993060T3 (en)	2007-12-07	2024-12-20	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP5645217B2 (ja)	2007-12-07	2014-12-24	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	５，６−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
MX2010007026A (es) *	2007-12-21	2010-10-05	Merck Serono Sa	Derivados de triazoloxadiazoles.
BRPI0821327A2 (pt) *	2007-12-25	2015-06-16	Kissei Pharmaceutical	Derivado de catecol, composição farmacêutica contendo o mesmo, uso do derivado de catecol, e uso da composição farmacêutica
US8188131B2 (en) *	2008-02-07	2012-05-29	Massachusetts Eye & Ear Infirmary	Compounds that enhance Atoh1 expression
ES2442945T3 (es)	2008-03-31	2014-02-14	Vertex Pharmaceuticals Inc.	Derivados de piridilo como moduladores del CFTR
WO2009131956A1 (en) *	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising triazole derivatives
WO2009131947A2 (en) *	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising pyridazine derivatives
US20100099677A1 (en) *	2008-04-21	2010-04-22	Institute For Oneworld Health	Compounds, Compositions and Methods Comprising Thiazole Derivatives
EP2278879B1 (en) *	2008-04-21	2016-06-15	PATH Drug Solutions	Compounds, compositions and methods comprising oxadiazole derivatives
US20090264433A1 (en) *	2008-04-21	2009-10-22	Institute For Oneworld Health	Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131954A2 (en) *	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) *	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
KR101787112B1 (ko) *	2008-06-09	2017-11-15	루드비히-막시밀리안스-우니버지테트 뮌헨	신경변성 질환 및/또는 단백질 응집과 연관된 질환과 관련된 단백질의 응집을 억제하기 위한 신규 약물
EP2300442A2 (en) *	2008-06-24	2011-03-30	Irm Llc	Compounds and methods for modulating g protein-coupled receptors
US20110237528A1 (en) *	2008-09-19	2011-09-29	Institute For Oneworld Health	Compositions and methods comprising imidazole and triazole derivatives
ES2542873T3 (es)	2009-02-10	2015-08-12	Monsanto Technology Llc	Composiciones y procedimientos de control de nemátodos
JP5620129B2 (ja) *	2009-03-19	2014-11-05	富士フイルム株式会社	光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
US8511216B2 (en) *	2009-03-30	2013-08-20	Kanzaki Kokyukoki Mfg. Co., Ltd.	Hydraulic actuator unit
US8343976B2 (en) *	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en)	2009-05-13	2013-12-04	Hannelore Breitenbach-Koller	Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
EP2435080A2 (en)	2009-05-29	2012-04-04	Abbott Laboratories	Pharmaceutical compositions for the treatment of pain
AR076984A1 (es)	2009-06-08	2011-07-20	Merck Serono Sa	Derivados de pirazol oxadiazol
US9849146B2 (en) *	2009-07-20	2017-12-26	Rutgers, The State University Of New Jersey	Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
PL2462276T3 (pl) *	2009-08-05	2015-04-30	Int Paper Co	Dodatek do suchego arkusza z celulozowej masy puchowej
PH12012500938A1 (en) *	2009-11-13	2016-09-16	Receptos Llc	Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CA2986521C (en)	2009-11-13	2020-06-30	Celgene International Ii Sarl	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
RU2711481C2 (ru)	2010-03-25	2020-01-17	Вертекс Фармасьютикалз Инкорпорейтед	ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK2555754T3 (en)	2010-04-07	2016-04-18	Vertex Pharma	Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
HUE056525T2 (hu)	2010-04-07	2022-02-28	Vertex Pharma	3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
EP3381899B1 (en)	2010-04-22	2021-01-06	Vertex Pharmaceuticals Incorporated	Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2600865B1 (en) *	2010-08-05	2018-11-14	Université de Lille	Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2608779A2 (en)	2010-08-23	2013-07-03	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
ES2758841T3 (es)	2011-05-13	2020-05-06	Celgene Int Ii Sarl	Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
US8945605B2 (en)	2011-06-07	2015-02-03	Parion Sciences, Inc.	Aerosol delivery systems, compositions and methods
US8778383B2 (en)	2011-06-07	2014-07-15	Parion Sciences, Inc.	Methods of treatment
US20140094465A1 (en) *	2011-06-10	2014-04-03	N30 Pharmaceuticals, Inc.	Compounds as S-Nitrosoglutathione Reductase Inhibitors
AR086745A1 (es)	2011-06-27	2014-01-22	Parion Sciences Inc	3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) *	2011-09-08	2013-10-07	중앙대학교 산학협력단	신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
WO2013070961A1 (en)	2011-11-08	2013-05-16	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
DK2806859T3 (da)	2012-01-25	2019-08-05	Vertex Pharma	Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
US9598395B2 (en)	2012-03-23	2017-03-21	The Regents Of The University Of California	Premature-termination-codons readthrough compounds
KR102109223B1 (ko)	2012-05-29	2020-05-11	패리온 사이언스 인코퍼레이티드	안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드
UA114915C2 (uk) *	2012-07-02	2017-08-28	Монсанто Текнолоджи Ллс	Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SG11201503365YA (en)	2012-11-02	2015-06-29	Vertex Pharma	Pharmaceutical compositions for the treatment of cftr mediated diseases
AP2015008441A0 (en)	2012-12-13	2015-05-31	Novartis Ag	Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors
US9029382B2 (en)	2012-12-17	2015-05-12	Parion Sciences, Inc.	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
CA2896686A1 (en)	2012-12-17	2014-06-26	Parion Sciences, Inc.	3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
MX379300B (es)	2012-12-17	2025-03-11	Parion Sciences Inc	Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
EP3113619A4 (en) *	2014-03-06	2017-09-13	PTC Therapeutics, Inc.	Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015154064A2 (en)	2014-04-04	2015-10-08	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CA2944140C (en)	2014-04-15	2022-10-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
ES2743184T3 (es)	2014-06-03	2020-02-18	Novartis Ag	Derivados de pirimido[4,5-b]quinolin-4,5(3H,10H)-diona como supresores de mutaciones finalizadoras
WO2015186061A1 (en)	2014-06-03	2015-12-10	Novartis Ag	Pyridopyrimidinedione derivatives
EA030374B1 (ru)	2014-06-03	2018-07-31	Новартис Аг	Производные нафтиридиндиона
CN105461650B (zh) *	2014-09-12	2018-04-13	杭州普晒医药科技有限公司	一种噁二唑化合物的溶剂化物及其制备方法
PL3203840T3 (pl)	2014-10-06	2021-01-11	Vertex Pharmaceuticals Incorporated	Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
CN104292180A (zh) *	2014-10-12	2015-01-21	湖南华腾制药有限公司	一种恶二唑衍生物的制备方法
US10174012B2 (en)	2014-11-04	2019-01-08	The University Of Kansas	LKB1-AMPK activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) *	2014-11-06	2016-05-12	Concert Pharmaceuticals, Inc.	Phenyloxadiazole benzoic acids
US9994559B2 (en)	2014-12-17	2018-06-12	King's College London	Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
CN106316885B (zh) *	2015-07-03	2019-02-12	普济生物科技（台州）有限公司	一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
BR112018008838A8 (pt)	2015-10-30	2019-02-26	Ptc Therapeutics Inc	método para tratar, prevenir, melhorar ou administrar uma doença epiléptica
EP3377476B1 (en) *	2015-11-16	2022-10-26	PTC Therapeutics, Inc.	Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
EP3405587A4 (en)	2015-12-23	2019-10-30	Moonshot Pharma LLC	METHOD FOR TRIGGERING AN IMMUNE REACTION THROUGH READ THROUGH PROMOTION OF A PREVIOUS TERMINATION CODON
TW201808922A (zh) *	2016-06-20	2018-03-16	台灣神隆股份有限公司	製備阿塔魯仁及其中間體的方法
GB201610867D0 (en)	2016-06-22	2016-08-03	King S College London	Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) *	2016-08-15	2022-04-15	广州明药科技有限公司	Ataluren的合成方法
WO2018047139A1 (en) *	2016-09-12	2018-03-15	Aurigene Discovery Technologies Limited	Compounds as modulators of tigit signalling pathway
US11207300B2 (en)	2016-09-13	2021-12-28	Marco Cipolli	Method of treatment of Shwachman-diamond syndrome
US11439623B2 (en)	2017-04-04	2022-09-13	Case Western Reserve University	Method of modulating ribonucleotide reductase
US11654135B2 (en)	2017-06-22	2023-05-23	Moonshot Pharma Llc	Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
US11795196B2 (en)	2017-12-15	2023-10-24	Stealth Biotherapeutics Inc.	Mitochondria-targeting peptides
WO2020078894A1 (en)	2018-10-15	2020-04-23	Academisch Medisch Centrum	Oncotherapeutic combinations
KR102658031B1 (ko)	2018-12-27	2024-04-18	제이투에이치바이오텍 (주)	근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
WO2020210432A1 (en)	2019-04-10	2020-10-15	Ptc Therapeutics, Inc.	Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
CN110987847B (zh) *	2019-12-11	2021-02-19	苏州今蓝纳米科技有限公司	1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) *	2020-05-12	2020-09-18	石家庄市度智医药科技有限公司	一种制备阿塔鲁伦的方法
CN113045510B (zh) *	2021-03-31	2022-05-27	北京大学生命科学华东产业研究院	一种阿塔鲁伦的制备方法
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies
CN116217508B (zh) *	2022-12-15	2024-12-17	浙江工业大学	一类用于保护β细胞来治疗II型糖尿病的噁二唑类化合物及其制备方法和应用
US11932632B1 (en)	2023-10-13	2024-03-19	King Faisal University	N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en)	2023-11-02	2024-04-16	King Faisal University	3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL291628A (no) *	1962-04-17
US3325446A (en)	1964-04-17	1967-06-13	Allied Chem	Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) *	1975-03-05	1977-05-10	E. R. Squibb & Sons, Inc.	3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en)	1975-06-06	1976-12-10	Takeda Chem Ind Ltd	A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) *	1975-07-28	1977-04-05	Sandoz, Inc.	Oxadiazolyl benzamides
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4166732A (en) *	1977-05-12	1979-09-04	Monsanto Company	Oxadiazol-5-yl-benzoates
US4135910A (en) *	1977-05-12	1979-01-23	Monsanto Company	Oxadiazol-3-yl-benzoates as plant growth regulants
US4165910A (en) *	1977-10-25	1979-08-28	Bunker Ramo Corporation	Electrical connector
ZA791659B (en)	1978-04-17	1980-04-30	Ici Ltd	Process and apparatus for spraying liquid
US4268299A (en) *	1978-08-17	1981-05-19	Monsanto Company	Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) *	1978-08-17	1980-07-01	Monsanto Company	2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
DE3173083D1 (en)	1980-03-22	1986-01-16	Fbc Ltd	Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
GB8504253D0 (en)	1985-02-19	1985-03-20	Ici Plc	Electrostatic spraying apparatus
DE3815221C2 (de)	1988-05-04	1995-06-29	Gradinger F Hermes Pharma	Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en)	1992-12-01	1993-01-20	Coffee Ronald A	Charged droplet spray mixer
GB9226717D0 (en)	1992-12-22	1993-02-17	Coffee Ronald A	Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de)	1993-06-23	1995-01-05	Fahlberg List Pharma Gmbh	2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) *	1993-10-27	1996-01-16	Neurogen Corporation	Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406171D0 (en)	1994-03-29	1994-05-18	Electrosols Ltd	Dispensing device
GB9406255D0 (en)	1994-03-29	1994-05-18	Electrosols Ltd	Dispensing device
TW343965B (en)	1994-03-30	1998-11-01	Hoffmann La Roche	Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en)	1994-05-27	1994-07-13	Electrosols Ltd	Dispensing device
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) *	1995-01-20	2000-06-06	University Of Massachusetts	Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
US5970974A (en)	1995-03-14	1999-10-26	Siemens Aktiengesellschaft	Dosating unit for an ultrasonic atomizer device
ES2140069T3 (es)	1995-03-14	2000-02-16	Siemens Ag	Dispositivo atomizador ultrasonico con unidad dosificadora de precision desmontable.
IL123191A0 (en)	1995-09-07	1998-09-24	Novartis Ag	Substituted phosphinic compounds and their use as pharmaceuticals
WO1997039745A1 (en)	1996-04-19	1997-10-30	Sloan-Kettering Institute For Cancer Research	Use of inhaled retinoids in the prevention of cancer
CN1216534A (zh) *	1996-04-26	1999-05-12	日本曹达株式会社	杂环取代的新颖苯衍生物和除草剂
DE19620041A1 (de) *	1996-05-17	1998-01-29	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
US6034106A (en) *	1996-06-07	2000-03-07	Merck & Co., Inc.	Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
CA2257206A1 (en)	1996-06-07	1997-12-11	Gui-Bai Liang	Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de)	1996-07-01	1998-01-08	Basf Ag	Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en)	1997-01-31	1999-07-16	Du Pont	Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (es) *	1997-04-07	2009-11-30	Georgetown University	Analogos de cocaina.
US6004933A (en)	1997-04-25	1999-12-21	Cortech Inc.	Cysteine protease inhibitors
NZ504021A (en)	1997-10-17	2003-04-29	Systemic Pulmonary Delivery Lt	Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
WO1999021852A1 (fr) *	1997-10-27	1999-05-06	Nippon Soda Co., Ltd.	Nouveaux derives de benzoylpyrazole et herbicides
CN1292714B (zh)	1998-03-16	2012-08-01	诺瓦帝斯公司	气溶胶化活性剂的输送
CA2329712A1 (en)	1998-04-23	1999-10-28	Cortech Inc.	Cysteine protease inhibitors
CZ20011270A3 (cs)	1998-10-08	2001-09-12	Smithkline Beecham Plc	Tetrahydrobenzazepinové deriváty vhodné jako modulátory dopaminových receptorů D3
CA2346396C (en)	1998-10-09	2009-04-28	Janssen Pharmaceutica N.V.	4,5-dihydro-isoxazole derivatives and their pharmaceutical use
AU1455500A (en)	1998-10-29	2000-05-22	Trega Biosciences, Inc.	Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
DE69939752D1 (de) *	1998-12-23	2008-11-27	Smithkline Beecham Corp	4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
WO2000058304A1 (fr)	1999-03-26	2000-10-05	Shionogi & Co., Ltd.	Derives sulfonamides heterocycliques
WO2000058280A1 (fr)	1999-03-26	2000-10-05	Shionogi & Co., Ltd.	Derives de sulfonamide carbocyclique
WO2000058278A1 (en)	1999-03-26	2000-10-05	Shionogi & Co., Ltd.	β-AMINO ACID DERIVATIVES
CZ20013767A3 (cs)	1999-05-17	2002-04-17	Novo Nordisk A/S	Sloučenina, farmaceutický prostředek, pouľití sloučeniny a způsob léčení
UA71971C2 (en) *	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja)	1999-08-12	2001-09-11	Japan Tobacco Inc	ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) *	1999-08-19	2003-12-09	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en)	1999-12-14	2002-10-01	Ptc Therapeutics, Inc.	Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en)	2000-03-09	2001-09-13	Abbott Laboratories	Cyclic and bicyclic diamino histamine-3 receptor antagonists
AU2001243987A1 (en) *	2000-03-22	2001-10-03	Merck Frosst Canada & Co.	Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
AU2001248765A1 (en) *	2000-04-21	2001-11-12	Shionogi And Co., Ltd.	Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) *	2000-05-08	2000-06-28	Black James Foundation	Gastrin and cholecystokinin receptor ligands (11)
KR100858642B1 (ko)	2000-05-22	2008-09-17	아벤티스 파마슈티칼스 인크.	트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체
CN1328143A (zh)	2000-06-12	2001-12-26	上海博德基因开发有限公司	一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja)	2000-09-27	2002-04-10	Shionogi & Co Ltd	新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en)	2001-03-08	2001-04-05	Fujisawa Pharmaceutical Co., Ltd.	New compound
CA2342432A1 (en)	2001-03-28	2002-09-28	Christopher Norbert Johnson	Novel compound
GB0108102D0 (en) *	2001-03-30	2001-05-23	Pfizer Ltd	Compounds
JP4480941B2 (ja)	2001-04-19	2010-06-16	アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト	抗ウイルス剤としての新規アリールスルホンアミド
MXPA03011196A (es) *	2001-06-08	2004-10-28	Cytovia Inc	3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos.
JP2003081832A (ja) *	2001-06-26	2003-03-19	Takeda Chem Ind Ltd	レチノイド関連受容体機能調節剤
GB0115862D0 (en)	2001-06-28	2001-08-22	Smithkline Beecham Plc	Compounds
MY151199A (en) *	2001-11-02	2014-04-30	Rigel Pharmaceuticals Inc	Substituted diphenyl heterocycles useful for treating hcv infection
CA2495120A1 (en)	2002-08-09	2004-02-19	Astrazeneca Ab	Oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003264018A1 (en)	2002-08-09	2004-02-25	Astrazeneca Ab	Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en)	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
JP2006521344A (ja)	2003-03-28	2006-09-21	ファイザー・プロダクツ・インク	アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
CN104056278B (zh) *	2003-04-11	2017-01-18	Ptc 治疗公司	1,2,4‑噁二唑苯甲酸化合物
US20050075375A1 (en)	2003-05-14	2005-04-07	Anadys Pharmaceuticals, Inc.	Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en)	2003-12-18	2005-07-07	Astrazeneca Ab	Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en)	2003-12-22	2010-06-29	Justin Stephen Bryans	Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en)	2004-02-03	2005-08-25	Astrazeneca Ab	Treatment of gastro-esophageal reflux disease (gerd)
MX2007004484A (es)	2004-10-13	2007-06-25	Ptc Therapeutics Inc	Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
EP1874306B1 (en) *	2005-04-08	2012-07-04	PTC Therapeutics, Inc.	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US9289398B2 (en)	2006-03-30	2016-03-22	Ptc Therapeutics, Inc.	Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en)	2006-04-19	2007-11-01	Brown University	Therapeutic compositions containing modified class i slrp proteins
RU2495030C2 (ru)	2006-09-08	2013-10-10	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Способы получения 1,2,4-оксадиазолбензойных кислот
HUE028503T2 (en)	2006-09-25	2016-12-28	Ptc Therapeutics Inc	Crystalline Forms of 3- [5- (2-Fluorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid
KR20160128468A (ko)	2006-10-12	2016-11-07	피티씨 테라퓨틱스, 인크.	넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
WO2008127364A2 (en)	2006-10-13	2008-10-23	Myriad Genetics, Inc.	Antiviral compounds and use thereof
US20110177999A1 (en)	2007-08-09	2011-07-21	Vertex Pharmaceuticals Incorporated	Therapeutic Combinations Useful in Treating CFTR Related Diseases
AU2008306885B2 (en)	2007-10-04	2013-12-05	Merck Serono S.A.	Oxadiazole derivatives
EP2614827B1 (en)	2007-10-26	2017-06-28	Academisch Ziekenhuis Leiden	Means and methods for counteracting muscle disorders
ES2594302T3 (es)	2007-12-17	2016-12-19	The Regents Of The University Of Michigan	Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético
EP2300442A2 (en)	2008-06-24	2011-03-30	Irm Llc	Compounds and methods for modulating g protein-coupled receptors
JP2012505223A (ja)	2008-10-07	2012-03-01	エムペックス・ファーマシューティカルズ・インコーポレーテッド	薬物動態の改善のためのエアゾールフルオロキノロン配合物
RU2398770C1 (ru)	2009-03-27	2010-09-10	Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН)	Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

2004
- 2004-04-09 CN CN201410119475.2A patent/CN104056278B/zh not_active Expired - Lifetime
- 2004-04-09 DK DK19174887.0T patent/DK3549936T3/da active
- 2004-04-09 EP EP14188816.4A patent/EP2910551B1/en not_active Expired - Lifetime
- 2004-04-09 PT PT191748870T patent/PT3549936T/pt unknown
- 2004-04-09 ES ES14188816.4T patent/ES2624610T3/es not_active Expired - Lifetime
- 2004-04-09 PT PT161706304T patent/PT3103800T/pt unknown
- 2004-04-09 ES ES19174887T patent/ES2881198T3/es not_active Expired - Lifetime
- 2004-04-09 DK DK19209758.2T patent/DK3632902T3/da active
- 2004-04-09 DK DK14188816.4T patent/DK2910551T3/en active
- 2004-04-09 DK DK17204895.1T patent/DK3345895T3/da active
- 2004-04-09 KR KR1020057019319A patent/KR101134188B1/ko active IP Right Grant
- 2004-04-09 UA UAA200510644A patent/UA84420C2/ru unknown
- 2004-04-09 ES ES16170630.4T patent/ES2679108T3/es not_active Expired - Lifetime
- 2004-04-09 SI SI200432484T patent/SI3345895T1/sl unknown
- 2004-04-09 SI SI200432514T patent/SI3632902T1/sl unknown
- 2004-04-09 DK DK04759404.9T patent/DK1618098T3/en active
- 2004-04-09 EP EP17153046.2A patent/EP3178816A1/en not_active Withdrawn
- 2004-04-09 PL PL21169137.3T patent/PL3889142T3/pl unknown
- 2004-04-09 EP EP21169137.3A patent/EP3889142B1/en not_active Expired - Lifetime
- 2004-04-09 PT PT211691373T patent/PT3889142T/pt unknown
- 2004-04-09 EP EP19209758.2A patent/EP3632902B1/en not_active Expired - Lifetime
- 2004-04-09 EP EP19174887.0A patent/EP3549936B1/en not_active Expired - Lifetime
- 2004-04-09 ES ES21169137T patent/ES2926542T3/es not_active Expired - Lifetime
- 2004-04-09 PL PL19174887T patent/PL3549936T3/pl unknown
- 2004-04-09 EP EP17204895.1A patent/EP3345895B1/en not_active Expired - Lifetime
- 2004-04-09 ES ES19209758T patent/ES2887054T3/es not_active Expired - Lifetime
- 2004-04-09 HU HUE17204895A patent/HUE047569T2/hu unknown
- 2004-04-09 NZ NZ543263A patent/NZ543263A/en not_active IP Right Cessation
- 2004-04-09 DK DK16170630.4T patent/DK3103800T3/en active
- 2004-04-09 EP EP16170630.4A patent/EP3103800B1/en not_active Expired - Lifetime
- 2004-04-09 HU HUE21169137A patent/HUE059464T2/hu unknown
- 2004-04-09 PT PT47594049T patent/PT1618098E/pt unknown
- 2004-04-09 TR TR2017/06226T patent/TR201706226T4/tr unknown
- 2004-04-09 PL PL16170630T patent/PL3103800T3/pl unknown
- 2004-04-09 ES ES04759404.9T patent/ES2528195T3/es not_active Expired - Lifetime
- 2004-04-09 BR BRPI0409319A patent/BRPI0409319B8/pt not_active IP Right Cessation
- 2004-04-09 MX MXPA05010747A patent/MXPA05010747A/es active IP Right Grant
- 2004-04-09 JP JP2006509896A patent/JP4851933B2/ja not_active Expired - Lifetime
- 2004-04-09 CN CN200480015905.0A patent/CN1802360B/zh not_active Expired - Lifetime
- 2004-04-09 SI SI200432445T patent/SI3103800T1/sl unknown
- 2004-04-09 PL PL17204895T patent/PL3345895T3/pl unknown
- 2004-04-09 EP EP22178089.3A patent/EP4101846B1/en not_active Expired - Lifetime
- 2004-04-09 HU HUE19209758A patent/HUE055434T2/hu unknown
- 2004-04-09 PT PT192097582T patent/PT3632902T/pt unknown
- 2004-04-09 HU HUE19174887A patent/HUE055056T2/hu unknown
- 2004-04-09 DK DK21169137.3T patent/DK3889142T3/da active
- 2004-04-09 SI SI200432222T patent/SI1618098T1/sl unknown
- 2004-04-09 AU AU2004229487A patent/AU2004229487B9/en not_active Expired
- 2004-04-09 ES ES17204895T patent/ES2770035T3/es not_active Expired - Lifetime
- 2004-04-09 PL PL19209758T patent/PL3632902T3/pl unknown
- 2004-04-09 PL PL04759404T patent/PL1618098T3/pl unknown
- 2004-04-09 PL PL14188816T patent/PL2910551T3/pl unknown
- 2004-04-09 EP EP04759404.9A patent/EP1618098B1/en not_active Expired - Lifetime
- 2004-04-09 ZA ZA200508298A patent/ZA200508298B/en unknown
- 2004-04-09 US US10/822,259 patent/US6992096B2/en not_active Expired - Lifetime
- 2004-04-09 PT PT141888164T patent/PT2910551T/pt unknown
- 2004-04-09 SI SI200432512T patent/SI3549936T1/sl unknown
- 2004-04-09 SI SI200432389A patent/SI2910551T1/sl unknown
- 2004-04-09 EA EA200501601A patent/EA009120B1/ru active Protection Beyond IP Right Term
- 2004-04-09 PT PT172048951T patent/PT3345895T/pt unknown
- 2004-04-09 WO PCT/US2004/011106 patent/WO2004091502A2/en active Application Filing
- 2004-04-09 HU HUE14188816A patent/HUE031794T2/en unknown
- 2004-04-09 HU HUE16170630A patent/HUE039026T2/hu unknown
- 2004-04-09 CA CA2521992A patent/CA2521992C/en not_active Expired - Lifetime
- 2004-04-09 SI SI200432521T patent/SI3889142T1/sl unknown
2005
- 2005-01-24 US US11/042,652 patent/US7772259B2/en active Active
- 2005-09-29 US US11/241,700 patent/US7202262B2/en not_active Expired - Lifetime
- 2005-10-10 IL IL171343A patent/IL171343A/en active IP Right Grant
- 2005-11-09 MA MA28594A patent/MA27802A1/fr unknown
- 2005-11-10 NO NO20055314A patent/NO332843B1/no active Protection Beyond IP Right Term
- 2005-11-10 CR CR8086A patent/CR8086A/es unknown
2006
- 2006-03-06 US US11/370,130 patent/US7419991B2/en not_active Expired - Lifetime
- 2006-03-06 US US11/370,229 patent/US7304080B2/en not_active Expired - Lifetime
2007
- 2007-01-08 HK HK07100245.6A patent/HK1093979A1/xx not_active IP Right Cessation
- 2007-03-14 US US11/724,408 patent/US7683082B2/en not_active Expired - Lifetime
2010
- 2010-01-21 US US12/691,005 patent/US8129540B2/en not_active Expired - Lifetime
- 2010-02-17 US US12/707,404 patent/US8017636B2/en not_active Expired - Lifetime
- 2010-03-08 US US12/719,443 patent/US8227494B2/en not_active Expired - Lifetime
2011
- 2011-07-15 JP JP2011156613A patent/JP5436500B2/ja not_active Expired - Fee Related
- 2011-08-18 US US13/212,221 patent/US8163782B2/en not_active Expired - Fee Related
2012
- 2012-03-23 US US13/427,932 patent/US8299105B2/en not_active Expired - Fee Related
- 2012-06-22 US US13/530,139 patent/US8486982B2/en not_active Expired - Lifetime
2013
- 2013-03-11 IL IL225161A patent/IL225161A/en active IP Right Grant
- 2013-06-19 US US13/921,269 patent/US8796322B2/en not_active Expired - Lifetime
2014
- 2014-06-18 US US14/307,747 patent/US8975287B2/en not_active Expired - Lifetime
2015
- 2015-01-16 CY CY20151100039T patent/CY1115870T1/el unknown
- 2015-01-28 US US14/607,132 patent/US9205088B2/en not_active Expired - Lifetime
- 2015-02-03 NO NO2015002C patent/NO2015002I1/no not_active IP Right Cessation
- 2015-03-18 HK HK15102788.5A patent/HK1202254A1/xx not_active IP Right Cessation
- 2015-04-16 HU HUS1500021C patent/HUS1500021I1/hu unknown
- 2015-04-17 CY CY2015017C patent/CY2015017I1/el unknown
- 2015-04-20 BE BE2015C025C patent/BE2015C025I2/fr unknown
- 2015-04-20 LU LU92698C patent/LU92698I2/xx unknown
- 2015-04-21 FR FR15C0030C patent/FR15C0030I2/fr active Active
- 2015-11-13 US US14/940,345 patent/US9861617B2/en not_active Expired - Lifetime
2016
- 2016-02-24 HK HK16102106.9A patent/HK1214253A1/zh not_active IP Right Cessation
2017
- 2017-05-03 CY CY20171100480T patent/CY1119001T1/el unknown
- 2017-12-04 US US15/830,405 patent/US10071081B2/en not_active Expired - Lifetime
2018
- 2018-07-20 CY CY20181100761T patent/CY1120446T1/el unknown
- 2018-12-21 HK HK18116432.2A patent/HK1257517A1/zh not_active IP Right Cessation
2020
- 2020-01-23 CY CY20201100063T patent/CY1122659T1/el unknown
2021
- 2021-08-30 CY CY20211100766T patent/CY1124464T1/el unknown
2022
- 2022-09-13 CY CY20221100605T patent/CY1125544T1/el unknown

Also Published As

Publication number	Publication date
US7772259B2 (en)	2010-08-10
JP2006522826A (ja)	2006-10-05
EP3345895B1 (en)	2019-12-04
DK3345895T3 (da)	2020-02-03
PT3889142T (pt)	2022-08-22
HK1257517A1 (zh)	2019-10-25
US8796322B2 (en)	2014-08-05
DK3889142T3 (da)	2022-09-12
IL171343A (en)	2013-06-27
EP3632902B1 (en)	2021-07-14
US20120178080A1 (en)	2012-07-12
ZA200508298B (en)	2007-01-31
CY1120446T1 (el)	2019-07-10
HK1093979A1 (en)	2007-03-16
KR101134188B1 (ko)	2012-04-12
UA84420C2 (ru)	2008-10-27
US6992096B2 (en)	2006-01-31
CN1802360B (zh)	2014-05-07
PL3549936T3 (pl)	2021-11-08
SI2910551T1 (sl)	2017-07-31
US20160081988A1 (en)	2016-03-24
NO20055314L (no)	2006-01-04
US7304080B2 (en)	2007-12-04
EP3549936A1 (en)	2019-10-09
EP4101846A1 (en)	2022-12-14
HUE059464T2 (hu)	2022-11-28
BRPI0409319A (pt)	2006-04-25
EP1618098A2 (en)	2006-01-25
NO332843B1 (no)	2013-01-21
US7683082B2 (en)	2010-03-23
HUE047569T2 (hu)	2020-04-28
EP1618098A4 (en)	2008-07-16
ES2624610T3 (es)	2017-07-17
CY1122659T1 (el)	2020-10-14
PT3632902T (pt)	2021-09-15
EP3889142A1 (en)	2021-10-06
US20060148864A1 (en)	2006-07-06
BE2015C025I2 (no)	2023-08-09
ES2528195T3 (es)	2015-02-05
US9205088B2 (en)	2015-12-08
US9861617B2 (en)	2018-01-09
EP3103800A1 (en)	2016-12-14
EP2910551A1 (en)	2015-08-26
PT3549936T (pt)	2021-07-14
ES2679108T3 (es)	2018-08-22
JP2011251981A (ja)	2011-12-15
DK3632902T3 (da)	2021-09-13
WO2004091502A3 (en)	2004-12-29
US7419991B2 (en)	2008-09-02
EP3632902A1 (en)	2020-04-08
CY2015017I2 (el)	2016-06-22
AU2004229487A1 (en)	2004-10-28
FR15C0030I2 (fr)	2015-07-24
HUE055056T2 (hu)	2021-10-28
US20070161687A1 (en)	2007-07-12
AU2004229487B9 (en)	2010-06-10
US20100216851A1 (en)	2010-08-26
MXPA05010747A (es)	2006-05-25
AU2004229487B2 (en)	2010-05-20
SI1618098T1 (sl)	2015-04-30
CN104056278A (zh)	2014-09-24
EA200501601A1 (ru)	2006-06-30
US20100121070A1 (en)	2010-05-13
JP5436500B2 (ja)	2014-03-05
JP4851933B2 (ja)	2012-01-11
WO2004091502A8 (en)	2005-11-24
DK2910551T3 (en)	2017-05-15
US20060035943A1 (en)	2006-02-16
HUE055434T2 (hu)	2021-11-29
CY1124464T1 (el)	2022-07-22
PL3889142T3 (pl)	2022-09-26
EP1618098B1 (en)	2014-11-19
US20140301978A1 (en)	2014-10-09
HK1214253A1 (zh)	2016-07-22
CY1115870T1 (el)	2016-06-22
US10071081B2 (en)	2018-09-11
CY1125544T1 (el)	2024-09-20
DK1618098T3 (en)	2015-01-12
KR20060009838A (ko)	2006-02-01
WO2004091502A2 (en)	2004-10-28
NO20055314D0 (no)	2005-11-10
US8975287B2 (en)	2015-03-10
HK1202254A1 (en)	2015-09-25
SI3103800T1 (sl)	2018-10-30
EP3889142B1 (en)	2022-06-15
LU92698I2 (fr)	2015-06-22
HUE039026T2 (hu)	2018-12-28
NZ543263A (en)	2008-12-24
BRPI0409319B1 (pt)	2019-11-12
FR15C0030I1 (no)	2015-05-22
US8129540B2 (en)	2012-03-06
PT3345895T (pt)	2020-01-29
US8163782B2 (en)	2012-04-24
US20040204461A1 (en)	2004-10-14
NO2015002I2 (no)	2015-02-03
HUS1500021I1 (hu)	2017-04-28
CN104056278B (zh)	2017-01-18
EP4101846B1 (en)	2023-08-02
PL3632902T3 (pl)	2021-12-20
US8017636B2 (en)	2011-09-13
US20130289007A1 (en)	2013-10-31
SI3549936T1 (sl)	2021-09-30
US20120277234A1 (en)	2012-11-01
US20050164973A1 (en)	2005-07-28
US20150148346A1 (en)	2015-05-28
US8486982B2 (en)	2013-07-16
PT2910551T (pt)	2017-05-22
US20060148863A1 (en)	2006-07-06
US20100168109A1 (en)	2010-07-01
SI3632902T1 (sl)	2022-01-31
HUE031794T2 (en)	2017-08-28
SI3345895T1 (sl)	2020-03-31
US7202262B2 (en)	2007-04-10
PT3103800T (pt)	2018-07-27
US8299105B2 (en)	2012-10-30
CA2521992A1 (en)	2004-10-28
PL3103800T3 (pl)	2018-11-30
CR8086A (es)	2006-12-19
EP3178816A1 (en)	2017-06-14
CN1802360A (zh)	2006-07-12
EP3103800B1 (en)	2018-06-13
US20180092887A1 (en)	2018-04-05
SI3889142T1 (sl)	2022-10-28
CY2015017I1 (el)	2016-06-22
EP3549936B1 (en)	2021-06-02
PL1618098T3 (pl)	2015-04-30
PL2910551T3 (pl)	2017-09-29
EP3345895A1 (en)	2018-07-11
EA009120B1 (ru)	2007-10-26
CA2521992C (en)	2013-02-05
DK3103800T3 (en)	2018-07-30
EP2910551B1 (en)	2017-02-15
BRPI0409319B8 (pt)	2021-05-25
CY1119001T1 (el)	2018-01-10
ES2881198T3 (es)	2021-11-29
US20110311486A1 (en)	2011-12-22
ES2887054T3 (es)	2021-12-21
MA27802A1 (fr)	2006-03-01
ES2926542T3 (es)	2022-10-26
ES2770035T3 (es)	2020-06-30
PT1618098E (pt)	2015-02-10
TR201706226T4 (tr)	2018-06-21
PL3345895T3 (pl)	2020-05-18
US8227494B2 (en)	2012-07-24
IL225161A (en)	2014-03-31
DK3549936T3 (da)	2021-07-12

Publication	Publication Date	Title
NO2015002I2 (no)	2015-02-03	Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
HK1090294A1 (en)	2006-12-22	Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate ;
EP1583750A4 (en)	2010-06-23	MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
DK1400518T3 (da)	2007-03-26	Heterocycliske forbindelser og lægemidler
NO20033203L (no)	2003-09-02	Terapeutiske heterocykliske forbindelser
HRP20080446T3 (en)	2008-10-31	Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
PL368403A1 (en)	2005-03-21	Aminoisoxazole derivatives active as kinase inhibitors
HK1132260A1 (en)	2010-02-19	1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
AU2003238179A8 (en)	2003-12-22	Herbicidally active heterocyclylalkynes
NO20031482L (no)	2003-04-01	Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer
AP2004002997A0 (en)	2004-03-31	Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
ATE290534T1 (de)	2005-03-15	4-(oxadiazol-3-yl)-1,4-diazabizyklo(3.2.2)- nonanderivate, ihre herstellung und therapeutische verwendung
DK1674456T3 (da)	2008-10-27	Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
HK1096960A1 (en)	2007-06-15	Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h- chromium-6-yl-derivatives and drugs containing said compounds
ATE237937T1 (de)	2003-05-15	Herbizide mischung, enthaltend ein 3-heterocyclyl-substituiertes benzoylderivat und ein adjuvant
IL172542A0 (en)	2006-04-10	2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
IS7766A (is)	2005-03-22	N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
NO20001391D0 (no)	2000-03-16	Ívelsesanordning for golfslag
ZA200309513B (en)	2004-12-08	Novel heterocyclic derivatives and medicinal use thereof.
IS6679A (is)	2003-01-14	Ný form (R)-N-[5-metýl-8-(4-metýlpíperasín-1-ýl)-1,2,3,4-tetrahýdró-2-naftýl]-4-morfólínóbensamíðs
NO20043483L (no)	2004-08-20	Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
GB0026578D0 (en)	2000-12-13	Heterocyclic derivatives useful as pharmaceutical agents
DK1265608T3 (da)	2008-12-08	Oxazolidinon tabletformulering
EG22745A (en)	2003-07-30	2-(3,5-Disbustituted-4-pyridyl)-4-(thienyl) thiazolyl or arylphenyl)1,30xazoline compounds
WO2001068063A3 (en)	2002-05-10	Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Legal Events

Date	Code	Title	Description
2016-02-08	MK1K	Patent expired